Splenic marginal zone lymphoma: a prognostic model for clinical use.

Claudio Tripodo, Vito Franco, Mario Lazzarino, Daniele Vallisa, Emilio Iannitto, Sergio Cortelazzo, Alessandra Tucci, Gianluca Gaidano, Claudio Tripodo, Viviana Minardi, Marco Ungari, Lorella Orsucci, Maurizio Frezzato, Domenico Novero, Francesco Merli, Emanuela Boveri, Luca Arcaini, Alessandro Pulsoni, Vincenzo Callea, Achille AmbrosettiMarco Paulli, Marcello Gambacorta, Nora Colombo, Vito Franco, Enrica Morra, Luca Baldini, Fabio Menestrina, Massimo Federico, Sara Burcheri, Mario Federico, Viviana Maria Minardi

Research output: Contribution to journalArticlepeer-review

111 Citations (Scopus)


The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. © 2006 by The American Society of Hematology.
Original languageEnglish
Pages (from-to)4643-4649
Number of pages7
Publication statusPublished - 2006

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Splenic marginal zone lymphoma: a prognostic model for clinical use.'. Together they form a unique fingerprint.

Cite this